Market Herald logo


Be the first with the news that moves the market
  • Algernon Pharmaceuticals (CSE:AGN) has received positive news from Health Canada’s Office of Clinical Trials for its drug Ifenprodil 
  • The drug is currently being tested for its effectiveness against COVID-19
  • Based on the news, the company has begun preparing its phase two clinical trial application 
  • Algernon plans to submit application next week 
  • Algernon Pharmaceuticals Inc (CAGN) is up 10 per cent, with shares trading at C$0.26 and a market cap $23 million 

Algernon Pharma (CSE:AGN) had received positive news from Health Canada regarding its drug Ifenprofil, which is currently being tested against COVID-19.

Algernon were given positive news from the governing body, regarding a potential phase two COVID-19 clinical study in Canada. 

Algernon stock bounced up 10 per cent on the news.

The company believes that Ifenprodil could reduce both the severity and the duration of a COVID-19 infection;

Based on the feedback, the company has begun preparations for a formal clinical trial application. The trial will focus on severely affected patients with COVID-19.

Upon approval, Algernon has committed to initiating trials as soon as possible.

The company’s CEO Christopher Moreau stated that this was very good news for the company.

“Receiving positive feedback from a major regulatory body is another significant step as we work to investigate our repurposed drug Ifenprodil as a possible therapeutic treatment for COVID-19,” he said.

Algernon has stated it will submit its application for the phase two trial within the next week and has been advised all COVID-19 related applications are being expedited by the regulator.

Furthermore, the company is working to support a planned investigator-led Ifenprodil COVID-19 clinical trial in South Korea. Investigator led clinical trials are trials instigated by a research institute or government health body, not a pharmaceutical manufacturer.

Algernon is specialist drug re-purposing company. The company investigate already regulatory approved medications for new disease applications.

Algernon Pharmaceuticals Inc (CAGN) is up 10 per cent, with shares trading for C$0.26 at 3:32pm EST. 

More From The Market Herald
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).

" LevelJump Healthcare (TSXV:JUMP) announces $2.5M private placement

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

" Leveljump Healthcare (TSXV:JUMP) provides corporate update

Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision.

" PharmaDrug (CSE:PHRX) engages Octagon Media for an investor marketing campaign

PharmaDrug Inc. (PHRX) has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.